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PUMA is a proapoptotic BCL-2 family member that
drives the apoptotic response to a diversity of
cellular insults. Deciphering the spectrum of PUMA
interactions that confer its context-dependent pro-
apoptotic properties remains a high priority goal.
Here, we report the synthesis of PUMASAHBs, struc-
turally stabilized PUMA BH3 helices that, in addition
to broadly targeting antiapoptotic proteins, directly
bind to proapoptotic BAX. NMR, photocrosslinking,
and biochemical analyses revealed that PUMA
SAHBs engage an a1/a6 trigger site onBAX to initiate
its functional activation. We further demonstrated
that a cell-permeable PUMA SAHB analog induces
apoptosis in neuroblastoma cells and, like expressed
PUMA protein, engages BCL-2, MCL-1, and BAX.
Thus, we find that PUMA BH3 is a dual antiapoptotic
inhibitor and proapoptotic direct activator, and its
mimetics may serve as effective pharmacologic trig-
gers of apoptosis in resistant human cancers.
INTRODUCTION
The cellular decision to live or die is adjudicated by members of
the BCL-2 protein family, which executes the activation or sup-
pression of mitochondrial apoptosis (Llambi et al., 2011). BCL-
2 proteins are classified into three groups based on sequence
homology and function. Antiapoptotic members such as BCL-2
contain up to four BCL-2 homology (BH) domains, whereas the
multidomain proapoptotic proteins, including BAX and BAK,
contain three BH domains. A heterogeneous group of proteins
that contain only the BH3 motif function as afferent sensors of
stress. These so-called ‘‘BH3-only’’ proteins relay proapoptotic
signals to the multidomain members, which ultimately render a
life or death decision based upon the overall balance between
the degree of stress and the antiapoptotic reserve. p53-upregu-
latedmodulator of apoptosis (PUMA) is one such BH3-only pro-
tein that was first identified as a transcriptional target of p53 (Han
et al., 2001; Nakano and Vousden, 2001; Yu et al., 2001). p53
deletion and mutagenesis can effectively blunt PUMA upregula-
tion, which may contribute to the pathogenesis, maintenance,
and chemoresistance of human cancer; reconstituting PUMA
function in this context can effectively reactivate apoptosis,888 Chemistry & Biology 20, 888–902, July 25, 2013 ª2013 Elsevier Leither alone or in combination with other agents (Yu et al.,
2001, 2006). Although oncogenesis was not observed in
Puma/ mice (Erlacher et al., 2006), PUMA is frequently down-
regulated across a broad spectrum of human cancers (Berou-
khim et al., 2010), suggesting that it may function as a tumor
suppressor in combination with other predisposing factors.
Indeed, deletion of even one Puma allele in Bim/ mice in-
creased the incidence of lymphoma (Erlacher et al., 2006).
Puma/ cells manifest reduced sensitivity to a variety of
p53-dependent and independent insults, including irradiation,
DNA-damaging agents, cytokine withdrawal, hypoxia, and
endoplasmic-reticulum stress (Jeffers et al., 2003; Luo et al.,
2005; Reimertz et al., 2003; Villunger et al., 2003; Yu and Zhang,
2008; Yu et al., 2001). These data highlight the importance of
PUMA’s role in apoptosis regulation in health and disease and
the potential of PUMA-based therapeutics to alternatively
enhance chemo- and radiosensitivity in the context of cancer
treatment or mitigate damage to host tissues through targeted
PUMA inhibition (Mustata et al., 2011). Thus, deciphering the
spectrum of PUMA interactions that confer its context-depen-
dent proapoptotic properties remains a high priority goal.
The BH3-only protein interaction circuit is believed to induce
apoptosis by two complementary mechanisms. The first is by
BH3-only protein-mediated ‘‘inhibition of the inhibitors’’ of cell
death (Uren et al., 2007; Willis et al., 2007). That is, the BH3 motif
of BH3-only proteins engages the canonical BH3-binding groove
of antiapoptotic targets to neutralize their capacity to bind and
block the multidomain proapoptotic effectors BAX and BAK. In
addition, select members of the BH3-only class of apoptotic pro-
teins have been shown to directly bind and activate BAK and
BAX at discrete canonical (Czabotar et al., 2013; Dai et al.,
2011; Leshchiner et al., 2013; Moldoveanu et al., 2013) and, in
the case of BAX, noncanonical (Gavathiotis et al., 2008, 2010;
Leshchiner et al., 2013) BH3-binding sites. Whereas structural
and biochemical data support direct and functional interactions
for the BH3 domains of BIM and BID with BAX and BAK (Czabo-
tar et al., 2013; Gavathiotis et al., 2008, 2010; Leshchiner et al.,
2013; Moldoveanu et al., 2006, 2013; Walensky et al., 2006),
the direct binding capability of the PUMA BH3 helix is
unresolved.
A series of studies that employed in vitro functional assays,
and cellular and in vivo analyses, have yielded conflicting results
regarding the existence and potential mechanistic role of direct
PUMA interactions with BAX and/or BAK. A physical association
between PUMA protein and BAX has been shown in bacterial
two-hybrid assays (Cartron et al., 2004), yeast cells (Gallenne
et al., 2009), in vitro and mammalian cell coimmunoprecipitationtd All rights reserved
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2009), and by fluorescence resonance energy transfer analysis
(Zhang et al., 2009), indicating that the two proteins can interact.
Puma/Bim/Bid/ knockout (TKO) mice show develop-
mental defects that are reminiscent of, although perhaps less se-
vere than (Villunger et al., 2011), those observed inBax/Bak/
mice, suggesting that eliminating key direct activators may be
tantamount to knocking out Bax and Bak altogether (Ren et al.,
2010). However, a series of studies document that the proapo-
ptotic activity of PUMA instead derives from exclusive antiapop-
totic inhibition, citing the lack of direct interaction between
PUMA and BAX upon coimmunoprecipitation from cells
exposed to discrete stress stimuli (Callus et al., 2008; Jabbour
et al., 2009; Willis et al., 2007). In addition, a C-terminally trun-
cated form of PUMA that manifests decreased BAX-binding
activity retained proapoptotic potency equivalent to that of full-
length PUMA, suggesting that the contribution of PUMA-BAX
engagement, at least in this experimental context, was not
essential (Yee and Vousden, 2008). Such cellular analyses are
made all themore challenging by the proposed ‘‘hit-and-run’’ na-
ture of the transient interactions between direct BH3 activators
and BAX/BAK, potentially confounding coimmunoprecipitation-
based studies. Even liposomal release assays, which probe
functional activation of BAX and BAK upon administration of
discrete agonists/antagonists, have had mixed results with
PUMA BH3 (Du et al., 2011; Kuwana et al., 2005). Thus, the pur-
pose of this biochemical, structural, proteomic, and cellular
study is to interrogate the capacity of PUMA BH3 to directly
and functionally engage BAX, and thereby contribute to its pro-
apoptotic activity in vitro and in cells.
RESULTS
Design, Synthesis, and Antiapoptotic Binding Activity of
Hydrocarbon-Stapled PUMA BH3 Helices
Whereas select BH3-only proteins, like BID, are highly structured
and maintain an a-helical BH3 domain in the unbound state,
others are intrinsically disordered (Hinds et al., 2007) but un-
dergo a-helical folding of the BH3 domain upon binding to
compatible antiapoptotic grooves (Day et al., 2008). In dissecting
themechanism of BH3-mediated BAX activation, we determined
that a helical BID or BIM BH3 peptide, but not unfolded ones,
were capable of directly engaging full-length BAX (Walensky
et al., 2006). As synthetic PUMA BH3 peptides are predomi-
nantly unstructured in solution (Letai et al., 2002) (Figure S1A
available online), we first sought to stabilize the physiologically
relevant a-helical structure by insertion of an all-hydrocarbon
crosslink. By replacing i, i+4 pairs of native residues with nonnat-
ural amino acids bearing olefin tethers followed by ruthenium-
catalyzed olefin metathesis, we previously generated a variety
of stabilized alpha-helices of BCL-2 domains (SAHBs) modeled
after the BH3 motifs of BCL-2 family proteins (Pitter et al.,
2008; Stewart et al., 2010; Walensky et al., 2004). In designing
stapled peptides—whether for in vitro binding studies, cellular
localization analyses, structure determination, cellular signal
transduction studies, or in vivo activity analyses—synthetic iter-
ation is required to achieve optimal solubility, structural stability,
cell permeability, and biological activity for the desired applica-
tion. In the case of our prototype BIM SAHBA (Walensky et al.,Chemistry & Biology 20,2006), which potently bound to and activated BAX, adjustments
in both sequence and charge (e.g., 146-IWIAQELRXIGDX-
NAYYARR-166 [+2] to 145-EIWIAQELRXIGDXNAYYA-164 [1])
were required to enhance solubility and weaken binding potency
in order to capture the transient ‘‘hit-and-run’’ interaction by nu-
clear magnetic resonance (NMR) analysis, which is performed at
high micromolar concentration (Gavathiotis et al., 2008, 2010). In
contrast, for cellular work performed in the low micromolar
range, the prototype BIM SAHBA (+2 charge) was optimal (Gav-
athiotis et al., 2008; LaBelle et al., 2012), given its enhanced
target binding potency and capacity to penetrate intact cells.
Thus, as for our development of BIM and MCL-1 SAHBs for a
diversity of applications (Gavathiotis et al., 2008; LaBelle et al.,
2012; Stewart et al., 2010; Walensky et al., 2006), we initiated
our synthetic efforts here by generating a panel of PUMA
SAHB constructs (designated PUMA SAHBs A1-A8) of differen-
tial sequence composition, length, and charge. In a screening
fluorescence polarization binding assay against antiapoptotic
BCL-XLDC, we observed a binding affinity range of 2.6–13 nM
for this panel of PUMA SAHBA peptides (Figure 1A). Guided by
our experience with BIM SAHBA, we selected a compound
with midrange affinity bearing the most negative charge for
in vitro biochemical and structural analyses, given our goal of
evaluating functional interactions with BAX, in addition to the
antiapoptotic targets. For optimal comparison, we aimed to
examine a PUMA SAHB bearing a staple in the same location
used for our prior studies with BIM SAHBA. However, as for
BIM SAHBs (Gavathiotis et al., 2008), we also wanted to confirm
that any single staple location did not independently impact
biochemical activity. Therefore, we also generated a panel of
PUMA SAHBs A-L with differential localization of the hydrocar-
bon staple (Figure 1B). This ‘‘staple scanning’’ approach not
only serves to dissociate any individual staple location from
overall observed biochemical activity but also identifies the
best binders and, importantly, those key residues and interfaces
to avoid for staple placement, providing valuable structure-activ-
ity relationship information (Gavathiotis et al., 2008; Stewart
et al., 2010). In each case, PUMA SAHBs with hydrocarbon sta-
ple placements that avoid the core hydrophobic binding inter-
face and highly conserved BH3 residues, exhibit nanomolar
BCL-XLDC binding affinity in the 4–21 nM range (Figures 1B
and S1B). In contrast, staples that replace key hydrophobic or
charged residues of the binding interface, as found in PUMA
SAHBs C, E, I, and J, manifest relatively impaired binding activ-
ity. As would be predicted, positioning the staple directly at the
binding interface while also replacing the universally conserved
leucine residue, as in PUMA SAHBH, is most detrimental. Finally,
we sought to generate a negative control construct for PUMA
SAHBA1 by swapping the location of an alanine residue at posi-
tion 139 with the universally conserved leucine at position 141.
Importantly, PUMA SAHBA1 and its A139L/L141A double point
mutant, designated PUMA SAHBA1mut, exhibit similar, high per-
centage a-helical content, as assessed by circular dichroism
(Figure 1C). When the corresponding fluorescein isothiocyanate
(FITC)-derivatized analogs were subjected to antiapoptotic
protein binding analyses, PUMA SAHBA1 engaged BCL-2DC,
BCL-XLDC, BCL-wDC, MCL-1DNDC, and BFL-1/A1DC with
dissociation constants in the 20–35 nM range, whereas A139L/
L141A mutagenesis uniformly impaired binding activity,888–902, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 889
250240200 260
A1 
A2
A3
A4
A5
A6
A7
A8
A9
Sequence
 EQWAREIGAQLRXBADXLNAQYE
  QWAREIGAQLRXBADXLNAQYERR
  QWAREIGAQLRXBADXLNAQY 
EEQWAREIGAQLRXBADXLNAQYERR
     REIGAQLRXBADXLNAQYERR     
     REIGAQLRXBADXLNAQYERRR 
      EIGAQLRXBADXLNAQYERR 
      EIGAQLRXBADXLNAQYERRR
      EIGAQLRXBADXLNAQYERRRQEE
Sequence
131-153
130-155
132-152
132-155
135-155
135-156
136-155
136-156
136-159
PUMA SAHB
BCL-XLΔC (M)
KD (nM)
 -2
+1
  0
 -1
+1
+2
  0
+1
 -1
Charge
 EQWAREIGAQLRXBADXLNAQYE 
XQWAXEIGAQLRRBADDLNAQYE
 EXWARXIGAQLRRBADDLNAQYE
 EQXAREXGAQLRRBADDLNAQYE
 EQWXREIXAQLRRBADDLNAQYE
 EQWARXIGAXLRRBADDLNAQYE
 EQWAREIGAXLRRXADDLNAQYE
 EQWAREIGAQXRRBXDDLNAQYE
 EQWAREIGAQLRRXADDXNAQYE
 EQWAREIGAQLRRBAXDLNXQYE
 EQWAREIGAQLRRBADXLNAXYE
 EQWAREIGAQLRRBADDLXAQYX
143, 147
131, 135
132, 136
133, 137
134, 138
136, 140
140, 144
141, 145
144, 148
146, 150
147, 151
149, 153
Staple PositionSequence
A1
B1
C1
D1
E1
F1
G1
H1
I1
J1
K1
L1
KD (nM)
-2
-2
-1
-2
-2
-1
-2
-2
-2
-1
-1
-1
Charge
BCL-XLΔC (M)
-4x104
-2x104
0
2x104
4x104
6x104
8x104
10x104
PUMA SAHBA1
PUMA SAHBA1mut
mut = A139L/L141A
100*
96
% α-helicity
230210 220
PUMA SAHBA1
Anti-Apoptotic Protein (M)
10-10 10-9 10-8 10-7 10-6 10-5
0
25
50
75
100
BCL-2ΔC
BCL-XLΔC
MCL-1ΔNΔC
BFL-1/A1ΔC
BCL-wΔC 26 nM ± 2.4nM
20 nM ± 3.0nM
34 nM ± 5.5nM
35 nM ± 4.9nM
23 nM ± 4.6nM
> 400nM
> 400nM
> 400nM
> 400nM
> 400nM
KD
E
Y
Q
A
N
L
D
D
A
B
R
R
L
Q
A
G
I
E
R
A
W
Q
E
PUMA SAHBA
PUMA SAHBB
PUMA SAHBB
PUMA SAHBC
PUMA SAHBE
PUMA SAHBF
PUMA SAHBG
PUMA SAHBH
PUMA SAHBI
PUMA SAHBJ
PUMA SAHBK
PUMA SAHBL
A
12 ± 1.2
9.7 ± 1.1
2.1 ± 0.5
10 ± 16
13 ± 1.4
3.2 ± 0.8
13 ± 1.4
17 ± 2.0
10 ± 1.0
17 ± 2.9
5.3 ± 1.2
41 ± 4.9
7.9 ± 1.6
49 ± 6.1
9.0 ± 1.1
21 ± 3.6
>400
45 ± 7.9
97 ± 13
11 ± 4.0
4.0 ± 0.9
PUMA SAHB
B
PUMA SAHBA1mut
C D
Wavelength (nm)
%
 F
IT
C-
SA
HB
 B
ou
nd
%
 F
IT
C-
SA
HB
 B
ou
nd
%
 F
IT
C-
SA
HB
 B
ou
nd
M
ol
ar
 E
llip
tic
ity
 (θ
)
D
10-10 10-9 10-8 10-7 10-6 10-5
0
25
50
75
100
10-10 10-9 10-8 10-7 10-6 10-5
0
25
50
75
100
Figure 1. Sequence Composition and Antiapoptotic Binding Activity of Hydrocarbon-Stapled PUMA BH3 Peptides
(A and B) A series of FITC-PUMA SAHBA peptides of differential BH3 domain length (A) and FITC-PUMA BH3 (131–153) constructs with varying staple positions
(as reflected by the ‘‘staple walk’’ along the pictured helical wheel) (B) were synthesized and screened for BCL-XLDC binding activity by fluorescence polarization
assay. See also Figure S1B for separated views of the PUMA SAHB A1-L1 plots. X, stapling amino acid; B, norleucine.
(C) Circular dichroism of PUMA SAHBA1 and its A139L/L141A mutant demonstrated the marked a-helical structure of both stapled peptides in aqueous solution.
*, exceeds the calculated ideal a-helicity of an undecapeptide standard.
(D) FITC-PUMA SAHBA1 (solid lines) exhibits high affinity binding to the diversity of antiapoptotic BCL-2 family proteins, whereas A139L/L141A point mutagenesis
(dashed lines) markedly impairs binding activity, highlighting the BH3 sequence-dependence of PUMA SAHBA1 engagement.
Data are mean ± SD for experiments performed in triplicate. See also Figure S1 and Table S1.
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Thus, we find that hydrocarbon stapling of the PUMA BH3
domain can potently enforce a-helical structure (Figures 1C
and S1A) and the library of constructs obey predicted struc-
ture-activity relationships based upon BH3 sequence composi-
tion. Notably, PUMA SAHBA1 engages in high affinity,
sequence-specific binding interactions with all antiapoptotic
targets.
PUMA SAHB Directly Binds to BAX by Initial Interaction
at the a1/a6 Trigger Site
To determine if a PUMA BH3 helix could likewise directly bind to
the proapoptotic class of BCL-2 family proteins, as previously
observed for BIM SAHBs, we undertook an NMR analysis of
15N-BAX uponPUMASAHB titration. Of note, the BAX-activating
BIM BH3 interaction is transient, making the structural analysis
of this dynamic process especially challenging (Gavathiotis
et al., 2008, 2010). We thus employed PUMA SAHBA1, a rela-
tively weaker binding PUMA SAHBA that also possessed the
most negative charge (2) to enhance solubility for high concen-
tration NMR experiments. We observed weak but reproducible890 Chemistry & Biology 20, 888–902, July 25, 2013 ª2013 Elsevier Ldose-responsive backbone amide chemical shift changes in
a discrete subset of BAX residues localized within a1, the
a1-a2 loop, and a6, corresponding to the previously identified
binding site for a stapled BIM BH3 helix (Gavathiotis et al.,
2008) (Figure 2A). Upon increasing the PUMA SAHBA1:
15N-
BAX ratio from 1:1 to 4:1, a series of chemical shift changes
became more prominent in the a1-a2 loop (yellow), a2 (BH3)
(teal), and a9 (pink) (Figure 2B), three regions previously impli-
cated in BIM-BH3-triggered N-terminal loop opening, BAX
BH3 exposure, and C-terminal helix mobilization, respectively
(Gavathiotis et al., 2010). These PUMA-SAHB-induced allosteric
changes are consistent with induction of a major conformational
change that is transmitted from the N-terminal face through the
hydrophobic core to the C-terminal face, resulting in functional
activation of BAX.
To probe the PUMA SAHB interaction site on BAX by a second
and completely distinct experimental approach, we developed
and applied photoreactive PUMA SAHBs (pSAHBs). pSAHBs
contain differentially localized benzophenone moieties, which
covalently trap both static and dynamic protein interactors upon
UV irradiation and enable the explicit localization of intercalationtd All rights reserved
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Figure 2. NMR Analysis of 15N-BAX upon PUMA SAHBA1 Titration
(A and B) At a 1:1 ratio of PUMA SAHBA1:BAX, a series of chemical shift changes localize to surface residues of a1 and a6, corresponding to the previously
defined trigger site (purple) for BIM-BH3-induced direct BAX activation (A). Allosteric changes involving residues of the a1-a2 loop (yellow), a2 (teal), and a9 (pink),
as transmitted through the hydrophobic core (a4, a5), are also evident (A) and become more prominent upon titration up to a PUMA SAHBA1:BAX ratio of 4:1 (B).
Ca atoms of BAX residues that undergo significant chemical shift change upon exposure to PUMA SAHBA1 are represented as orange bars on the plot (top) and
orange spheres on the ribbon diagrams ofmonomeric BAX protein (PDB ID code 2K7W; calculated significance threshold > 0.007 ppm for 1:1 titration and > 0.011
for 4:1 titration).
See also Table S1.
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(Braun et al., 2010). To validate the binding specificity of PUMA
pSAHBs 1 and 2, we first conducted crosslinking analysis with
antiapoptotic BFL-1/A1DC, for which definitive structures are
known. We found that the differentially placed benzophenone
moieties in each PUMA pSAHB crosslinked to discrete subre-
gions of the canonical BH3 binding pocket (Figure S2), precisely
corresponding to the established structure of a PUMA BH3/
BFL-1/A1DC complex (Smits et al., 2008) (Protein Data Bank
[PDB] ID code 2VOF). Having validated the fidelity of PUMA
pSAHBs 1 and 2, we subjected full-length BAX to the crosslinking
analysis. We found that PUMA pSAHB-1 almost exclusively
crosslinked to BAX residues of the a1/a6 trigger site (Figure 3A),
whereas PUMA pSAHB-2 reacted with residues at the a1/a6
trigger site and a3 residues of the canonical BH3-binding pocket
(Figure 3B). BAX a9 effectively occludes the canonical BH3-bind-
ing pocket in the protein’s inactive state (Suzuki et al., 2000), and
our NMR study only detected a confluence of protein surfaceChemistry & Biology 20,chemical shift changes at the a1/a6 site upon ligand binding (Fig-
ure 2). Thus, the identified canonical pocket crosslinks are most
likely indicative of a compatible secondary binding interaction
that ensues upon allosteric release of a9 from the canonical
pocket, which is induced by initial BH3 engagement of the a1/
a6 trigger site. To explore this hypothesis, we repeated the
PUMA pSAHB crosslinking studies on a mutant form of BAX in
which the C terminus was deleted (BAXDC), thus exposing the
canonicalBH3-binding pocket from theoutset. Strikingly, thebal-
ance of crosslinks completely shifted for both PUMA pSAHBs in
favor of canonical pocket residues (Figures 3C and 3D). These
data support a model in which exposure of the canonical BH3-
binding pocket upon allosteric release of a9 reveals a secondary
PUMA BH3 interaction site that may be reflective of a sequential
BH3-mediated direct BAX activation mechanism.
To further dissect the capacity of PUMASAHBs to engage two
discrete BH3-binding sites on BAX, we developed BAX con-
structs for independent evaluation of the a1/a6 and canonical888–902, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 891
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Figure 3. BAX Interaction Site Analysis by PUMA SAHB Photoaffinity Labeling and Mass Spectrometry
(A) PUMA pSAHB-1 was incubated with full-length BAX, and the mixture was subjected to UV irradiation, streptavidin pull-down, electrophoresis, excision of the
crosslinked protein, trypsin proteolysis, and LC-MS/MS analysis. A single arginine substitution (A150R) wasmade in PUMApSAHB-1 to facilitate tryptic digestion
into shorter andmore identifiable fragments byMS. The plot (left) depicts the frequency of crosslinked sites identified across the BAX polypeptide sequence, with
(legend continued on next page)
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Figure 4. PUMA SAHBs Bind to Two
Geographically Distinct Sites on BAX
(A) Covalent tethering of the BAX C-terminal helix
to its binding groove by an installed A112C/V177C
disulfide bridge (GSSG, 0.5 mM) occludes the
canonical BH3-binding surface of full-length BAX.
In this context, only the a1/a6 trigger site is avail-
able for BH3 interaction.
(B) Both structural and MS analyses indicate that
activator BH3 helices bind to the exposed ca-
nonical pocket of BAXDC, a truncated BAX
construct in which the C-terminal helix is removed.
In this context, the canonical BH3-binding site on
BAX is preferred.
(C) FITC-PUMA SAHBF1 binds to BAX A112C/
V177C and BAXDC with KDs of 90 and 70 nM,
respectively, as measured by FP assay.
(D) FITC-PUMA SAHBA1 binds to BAX A112C/
V177C and BAXDC with KDs of 717 and 221 nM,
respectively.
(E) A139A/L141A mutagenesis of FITC-PUMA
SAHBA1 abrogates BAX-binding activity, high-
lighting the sequence specificity of the measured
FITC-PUMA SAHBA1 interactions with BAX
A112C/V177C and BAXDC.
(F) FITC-PUMA BH3 (aa 131–153) exhibited no
binding activity toward BAX A112C/V177C but
engaged BAXDC with a KD of 306 nM, suggesting
that the exposed canonical pocket is more
amenable to induced folding of an unstructured
PUMA BH3 peptide.
Data are mean ± SD for experiments performed in
triplicate.
See also Table S1.
Chemistry & Biology
Dissecting the Apoptotic Interactions of PUMA BH3BH3-binding sites. To isolate the a1/a6 trigger site at the
N-terminal face of BAX, wemade use of our previously described
BAX A112C/V177C construct, which under oxidizing conditions
locks the C-terminal a9 helix of BAX in place with an installed
disulfide tether, occluding the canonical BH3-binding site (Gav-
athiotis et al., 2010) (Figure 4A). We used BAXDC to evaluate
BH3-binding at the C-terminal site (Figure 4B), because we
essentially observed no a1/a6 site crosslinking when the C-ter-
minal helix is removed (Figures 3C and 3D). This is likely due to
ready access to the canonical pocket—as stably captured by
X-ray crystallography (Czabotar et al., 2013)—and bypass of
the native N-terminal triggering mechanism.crosslinked residues mapped onto the solution structure of monomeric BAX (PDB ID code 2K7W) (right) and
The C-terminal a9 helix of BAX has been removed from the structure to better visualize the crosslinked resi
(B–D) The corresponding analysis was performed for PUMA pSAHB-2 with full-length BAX (B), PUMA pSAHB
and PUMA pSAHB-2 with BAXDC (D). X, stapling amino acid; B, norleucine; U, 4-benzoyl-phenylalanine (Bp
See also Figure S2 and Table S1.
Chemistry & Biology 20, 888–902, July 25, 2013Each of the BAX constructs was
applied in fluorescence polarization (FP)
assays to probe the binding activities of
FITC-PUMA SAHBs F1 and A1, which
contain the F and A staples found in
PUMA pSAHBs 1 and 2, respectively.
Both FITC-PUMA SAHBs bound to BAX
A112C/V177C and BAXDC, indicating
dual compatibility for the geographicallydistinct BH3-binding sites. Whereas FITC-PUMA SAHBF1 ex-
hibited similar nanomolar affinity for each of the constructs
(KDs: 90 nM, BAX A112C/V177C; 70 nM, BAXDC), FITC-
PUMA SAHBA1 showed a 3-fold preference for BAXDC (KDs:
717 nM, BAX A112C/V177C; 221 nM, BAXDC). Yet, in cross-
linking experiments, the corresponding F- and A-stapled
pSAHBs both crosslinked to a1/a6 residues in full-length
BAX, and these N-terminal interactions were nearly eliminated
in favor of canonical site crosslinking upon removal of the C ter-
minus. These data support a mechanism in which activator
BH3 engagement of cytosolic, full-length BAX occurs at the
N-terminal site first, followed by a secondary compatiblecolored according to the frequency of occurrence.
dues of the canonical BH3-binding pocket.
-1 with C-terminal helix-deleted BAX (BAXDC) (C),
a).
ª2013 Elsevier Ltd All rights reserved 893
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Figure 5. PUMA SAHBA1 Triggers BAX-Mediated Liposomal and Cy-
tochrome c Release
(A) PUMA SAHBA1 triggered dose-responsive BAX-mediated liposomal
release of entrapped fluorophore (top), whereas BAX or PUMA SAHBs alone,
or the combination of PUMA SAHBA1mut with BAX (bottom), had little to no
effect. Data are mean ± SD for experiments performed in triplicate and
repeated twice.
(B) BAX/BAK-deficient mitochondria dose responsively released cytochrome
c upon incubation with recombinant BAX and increasing amounts of PUMA
SAHBA1, whereas BAX or PUMA SAHBs alone, or the combination of PUMA
SAHBA1mut with BAX, had little to no effect. Data are mean ± SD for experi-
ments performed in sextuplicate and repeated three times.
See also Table S1.
Chemistry & Biology
Dissecting the Apoptotic Interactions of PUMA BH3interaction at the canonical pocket once the C-terminal helix is
released from its binding groove.
Negative control FP studies further highlighted the specificity
of the observed FITC-PUMA SAHB binding activities, with894 Chemistry & Biology 20, 888–902, July 25, 2013 ª2013 Elsevier LFITC-PUMA SAHBA1 A139L/L141A showing no interaction with
either BAX A112C/V177C or BAXDC (Figure 4E). Interestingly,
the unmodified FITC-PUMA BH3 peptide (amino acids [aa]
131–153) demonstrated no binding activity toward BAX
A112C/V177C but displayed nanomolar binding affinity for
BAXDC (Figure 4F). These data mirror the results of our very first
comparative binding analyses of unmodified and hydrocarbon-
stapled BID BH3 peptides with full-length and C-terminally
deleted BAX (Walensky et al., 2006). The unstructured BID
BH3 peptide could readily bind by induced folding into the
exposed C-terminal deep pocket of BAXDC, but a prefolded
BH3 helix in the form of BID SAHB was required for interaction
with full-length BAX. This unexpected result suggested that
BH3-binding to full-length BAX was somehow different than
that observed for BAXDC. We considered the possibility that
the prefolded BID SAHB could be more effective than the
unfolded peptide at displacing the BAX C terminus to achieve
canonical site binding (Walensky et al., 2006). If such competi-
tion with an intramolecular helix was not energetically feasible,
as suggested by the original NMR analysis of full-length BAX (Su-
zuki et al., 2000), we alternatively hypothesized that a different
interaction site could exist, which ultimately led to our discovery
of the more shallow BH3-compatible binding site at the N-termi-
nal surface of BAX (Gavathiotis et al., 2008). Importantly, the
inability of the unmodified FITC-PUMA BH3 peptide to engage
oxidized BAX A112C/V177C, but readily bind to BAXDC, pro-
vides further evidence that the two BAX constructs indeed pre-
sent two geographically distinct BH3-binding surfaces.
PUMA SAHB Directly Activates BAX-Mediated Pore
Formation
To link the direct interaction between PUMA SAHB and BAX to
its functional activation, we employed a reductionist liposomal
system that measures BAX pore formation in a membrane envi-
ronment upon the addition of discrete reagents. Whereas treat-
ment with BAX, PUMA SAHBA1, or its A139L/L141A mutant
alone had little to no effect on the liposomes, the combination
of BAX and PUMA SAHBA1 yielded dose-responsive liposomal
release of entrapped fluorophore (Figure 5A). Point mutagenesis
of the PUMA-BH3-interacting surface completely abrogated the
effect (Figure 5B), underscoring the sequence-based specificity
of PUMA SAHBA1 activity. Likewise, in the context of BAX/BAK-
deficient mitochondria isolated from Alb-creposBaxflox/-Bak/
mice, dose-responsive release of cytochrome c was only
observed upon incubation with the combination of BAX and
PUMA SAHBA1. Again, the specificity of PUMA SAHBA1 activity
was confirmed by impairment of BAX-mediated cytochrome c
release upon SAHB mutagenesis. Whereas in the mitochondrial
assay, the effect of PUMA SAHBA1 on BAX activity can be ampli-
fied by simultaneous inhibition of membrane-embedded antia-
poptotic proteins, the requirement of PUMA SAHBA1 to initiate
BAX activation in both assays underscores the functional role
of the direct PUMA SAHB/BAX binding interaction in triggering
the membrane release activity of BAX.
PUMA SAHB Induces Caspase 3/7 Activation and Cell
Death by Engagement of Anti- and Proapoptotic Targets
We next aimed to correlate our in vitro biochemical and
structural findings to PUMA BH3 activity in cells. Among thetd All rights reserved
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Figure 6. Development and Evaluation of a
Cell-Permeable PUMA SAHB
(A and B) SH SY5Y cells were treated with the
indicated FITC-PUMA BH3 peptides (5 mM) in
serum-free media for 6 hr, followed by washing,
trypsinization, cellular lysis, electrophoresis of the
isolated supernatant, and fluorescence detection.
Whereas little to nounmodifiedPUMABH3peptide
or PUMA SAHBA1 fluorescence was detected in
the corresponding cellular lysates (A andB), PUMA
SAHBA2 demonstrated robust fluorescence (B).
(C) The cellular uptake of FITC-PUMA SAHBA2
was time dependent, as reflected by a progressive
increase in intracellular peptide that comigrated
with FITC-PUMA SAHBA2 marker peptide.
(D) Live cell confocal microscopy of SH SY5Y cells
treated with FITC-PUMA SAHBA2 demonstrated
its intracellular distribution (green). Prior to imag-
ing, the cells were treated with Hoechst dye (blue)
to label nuclei and CellMask Orange (orange-red)
to delineate the plasma membrane. Original
magnification, 1003.
(E) Cellular uptake of FITC-PUMA SAHBA2 was
dose responsively reduced by the addition of fetal
bovine serum (FBS; 0%, 2.5%, 5%, and 10% [v/v])
to the tissue culture medium.
(F) Addition of the indicated amounts of serum to
PUMA SAHBA2-treated SH SY5Y cells during the
initial 6 hr incubation period, dose responsively
reduced cytotoxicity, as measured at 24 hr (18 hr
after serum replacement to 10% [v/v]) by CellTiter-
Glo assay. Incubating SH SY5Y cells with vehicle
and media containing 0%, 2.5%, 5%, or 10%
serum for 6 hr, followed by serum replacement to
10% (v/v), had no independent effect on cell
viability, as measured by CellTiter-Glo at 24 hr.
Data are mean ± SD for experiments performed in
triplicate.
See also Figure S3 and Table S1.
Chemistry & Biology
Dissecting the Apoptotic Interactions of PUMA BH3BH3-only proteins, PUMA has been implicated as a major
driver of apoptosis induction in neurons and neuronal precursor
cells (Akhtar et al., 2006; Reimertz et al., 2003; Steckley et al.,
2007; Wyttenbach and Tolkovsky, 2006). Therefore, we exam-
ined the proapoptotic activity of PUMA SAHBA1 in neuroblas-
toma cells, which can mount a substantial and clinically rele-
vant apoptotic blockade (Goldsmith et al., 2012). We first
screened PUMA SAHBA1 for cellular uptake by treating SH
SY5Y neuroblastoma cells with its FITC-derivatized analog for
6 hr, followed by trypsinization, repeated washing, cellular lysis,
electrophoresis, and fluorescence scan detection. Of note, we
initially test for cell permeability in serum-free media to avoid
potential effects of serum on peptide exposure (Bird et al.,
2011; Braun et al., 2010; Pitter et al., 2008). A comparison of
lysates from cells treated with the unmodified FITC-PUMA
BH3 peptide and the corresponding A-stapled analog revealed
no significant intracellular peptide fluorescence (Figure 6A),
consistent with our prior observations that stapling of peptides
alone does not uniformly confer cellular penetrance, particularly
when the overall charge of the construct is less than 0 (Bernal
et al., 2007; Bird et al., 2011; Gavathiotis et al., 2008; Stewart
et al., 2010), as is the case with PUMA SAHBA1. To facilitate
cellular penetrance, we previously adjusted the overall charge
of a-helical stapled peptides from <0 to the 0 to +2 range,Chemistry & Biology 20,either by converting aspartic and glutamic acid residues to as-
paragines and glutamines (Bernal et al., 2007) or by shifting the
sequence composition to eliminate N- or C-terminal negatively
charged residues and/or include N- or C-terminal positively
charged residues (Gavathiotis et al., 2008; Stewart et al.,
2010; Walensky et al., 2004). In this case, we eliminated the
N-terminal glutamic acid of PUMA SAHBA1 and appended
two native C-terminal arginines, converting the overall peptide
charge from 2 to +1, while maintaining high a-helical content
(Figure S3A) and analogous binding activity (Figure 1A). When
the FITC-derivatized analog of this alternate construct, PUMA
SAHBA2, was subjected to cellular uptake analysis, a robust
fluorescent band was detected in the lysate of treated cells,
whereas the corresponding unmodified peptide again showed
no uptake (Figure 6B). As previously observed for a variety of
cell-permeable stapled peptides (Bernal et al., 2007; Takada
et al., 2012; Walensky et al., 2004), the uptake was time depen-
dent and the intracellular peptide proteolytically stable
(Figure 6C). Live cell confocal microscopy of FITC-PUMA-
SAHBA2-treated SH SY5Y cells further confirmed peptide up-
take (Figure 6D).
Whereas some stapled peptides manifest robust cellular up-
take and bioactivity in serum-containing tissue culture media
(Brown et al., 2013; Danial et al., 2008; Takada et al., 2012),888–902, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 895
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Figure 7. Proapoptotic Activity and Multi-
modal Interactions of PUMA BH3
(A–C) PUMA SAHBA2 dose responsively impaired
the viability of a series of neuroblastoma cell lines,
including, SH SY5Y, Kelly, and IMR5, as measured
by CellTiter-Glo at 24 hr after treatment (left col-
umn). The observed decrease in cell viability cor-
responded to dose-responsive caspase 3/7 acti-
vation, as measured by Caspase-Glo at 8 hr after
treatment (middle column). Data aremean ± SD for
experiments performed in triplicate. Incubation of
cellular lystates with biotinylated PUMA SAHBA3,
followed by streptavidin pull-down, washing,
electrophoresis of eluates, and BCL-2 family
western analysis, documented engagement of
native MCL-1, BCL-2, and BAX in all three neuro-
blastoma lines (right column).
(D and E) PUMA SAHBA2 dose responsively
impaired the viability of wild-type mouse embry-
onic fibroblasts (MEFs) but had little to no effect on
Bax/Bak/ MEFs, as measured by CellTiter-
Glo at 24 hr after treatment (left column).
Correspondingly, dose-responsive caspase 3/7
activation was observed in wild-type MEFs, but
not in Bax/Bak/ MEFs, as measured by
Caspase-Glo at 8 hr after treatment (right column).
Data are mean ± SD for experiments performed in
triplicate and repeated four times.
(F and G) Flag-Pumaa, its R142E or D147K mu-
tants, or vector control was transiently transfected
into human embryonic kidney 293T (HEK 293T)
cells and lysates subjected to immunoprecipita-
tion using Flag affinity beads, followed bywashing,
electrophoresis of eluates, and anti-MCL-1, BCL-
2, BAX, PUMA, and GAPDH western analysis.
See also Figure S4 and Table S1.
Chemistry & Biology
Dissecting the Apoptotic Interactions of PUMA BH3others demonstrate reduced uptake and activity in the presence
of serum, necessitating a serum-free window to facilitate cellular
exposure (Bernal et al., 2007; LaBelle et al., 2012). Here, we find
that the addition of serum dose responsively impaired the uptake
of PUMA SAHBA2 by SH SY5Y cells (Figure 6E), with optimal
peptide loading achieved in serum-free conditions by 6 hr
(Figure 6C). The level of intracellular peptide detected at 6 hr
correlated with the observed cytotoxicity, as measured after an
additional 18 hr incubation in the presence of 10% serum (Fig-
ure 6F). Importantly, varying the serum concentration from 0%
to 10% during the first 6 hr followed by full serum replacement
had no independent effect on cell viability (Figure 6F). Although
this does not rule out the possibility that viability impairment is
enhanced by the combination of serum withdrawal and PUMA896 Chemistry & Biology 20, 888–902, July 25, 2013 ª2013 Elsevier Ltd All rights reservedSAHBA2 treatment, the dose-responsive
decrease in PUMA SAHBA2 uptake ap-
pears to be the predominant mechanistic
effect of serum in shifting the cellular
response curves to the right (Figures 6E
and 6F).
With a cell-permeable version of PUMA
SAHB in hand and practical treatment
conditions defined, we exposed a series
of neuroblastoma cells, including SH
SY5Y, Kelly, and IMR5, to PUMA SAHBA2
in the absence of serum, followed by full serum replacement at
6 hr and cell viability measurement at 24 hr. In each case, a
dose-responsive impairment in cell viability was observed (Fig-
ures 7A–7C, left), which correlated with dose-responsive cas-
pase 3/7 activation, asmeasured at 8 hr (Figures 7A–7C,middle).
To investigate whether the observed caspase 3/7 activation and
cell death correlated with PUMA SAHB engagement of BCL-2
family targets, we incubated cellular lysates from each of the
three cell lines with an N-terminal biotinylated analog of PUMA
SAHBA, followed by streptavidin pull-down and western anal-
ysis. In each case, a diverse spectrum of BCL-2 family targets
was engaged, as reflected by PUMA SAHB pull-down of antia-
poptotic BCL-2 and MCL-1, and proapoptotic BAX (Figures
7A–7C, right). Taken together, these data demonstrate that
Chemistry & Biology
Dissecting the Apoptotic Interactions of PUMA BH3cell-permeable PUMA SAHBA2 can activate the death pathway
in neuroblastoma cells, and this biological activity correlates
with the capacity of a biotinylated PUMA BH3 helix to bind
both anti- and proapoptotic BCL-2 family members.
Specificity and Physiologic Relevance of PUMA SAHB
Activity
An important measure of proapoptotic specificity for ligands de-
signed to operate via the BCL-2 family pathway is whether death
induction occurs in a BAX/BAK-dependent fashion. Thus, we
treated wild-type and Bax/Bak/ mouse embryonic fibro-
blasts (MEFs) with PUMA SAHBA2 and measured cell viability
and caspase 3/7 activation, as performed for the neuroblastoma
cell lines. Albeit at a higher dosing range, PUMA SAHBA2 dose
responsively impaired cell viability of wild-type MEFs (Figure 7D,
left), with caspase 3/7 activation observed at the corresponding
doses that induced cell death (Figure 7D, right). In contrast, little
to no effect of PUMA SAHBA2 was observed in Bax
/Bak/
MEFs, with cell viability maintained in the 80%–100% range (Fig-
ure 7E, left) and no activation of caspase 3/7 observed (Figure 7E,
right).
We next explored whether or not the protein interactions of
stapled PUMA BH3 helices, and their documented functional
consequences, reflect the physiologic interactions of full-length
PUMA protein. Flag-Pumaa was transiently transfected into hu-
man embryonic kidney (HEK) 293T cells and immunoprecipi-
tated using anti-Flag resin. As observed for biotinylated PUMA
SAHBA3, Flag-PUMA engaged a diversity of anti- and proapo-
ptotic BCL-2 family targets, as reflected by western analysis
detection of coprecipitated BCL-2, MCL-1, and BAX (Figure 7F).
As for the PUMA SAHB pull-down (Figures 7A–7C, right), the
relative ratio of Flag-PUMA pull-down to protein input was
greater for antiapoptotic BCL-2 and MCL-1 than proapoptotic
BAX, reflecting either (1) the more stable nature of BH3/antia-
poptotic interactions compared to BH3/proapoptotic inter-
actions or (2) a frank preference for PUMA BH3 engagement of
antiapoptotic targets, and once this reservoir is saturated, direct
activation of proapoptotic targets can ensue.
Finally, we investigated whether disrupting key charge-charge
interaction pairs between the PUMA BH3 domain and its binding
sites on multidomain BCL-2 family proteins could be harnessed
to probe the selectivity of PUMA interactions. PUMA shares
striking sequence homology with BIM and BAX in the core
BH3 domain sequence, as reflected by the hydrophobic and
electrostatic distribution in the consensus L(K/R)R(I/M)(A/G)
D(D/E) (Figure S4A). The first positively charged residue of the
consensus consistently engages in a conserved electrostatic
interaction with a negatively charged residue at both canonical
and BAX a1/a6 BH3-binding sites, as exemplified by PUMA
R142/MCL-1 D237, BAX K64/BCL-2 D140, BAX K64/BAX
D102, and BIM R153/BAX E131 in the corresponding structures
(Figures S4B–S4E). However, the second negatively charged
residue of the consensus is less commonly engaged in a com-
plementary electrostatic pairing at canonical sites (e.g., PUMA
R142 in the PUMA BH3/MCL-1 complex, BAX E69 in the BAX
BH3/BAX complex) (Figures S4B and S4D) but explicitly en-
gages K21 at the BAX a1/a6 trigger site (e.g., BIM E158/BAX
K21 in the BIM BH3/BAX complex) (Figure S4E). Indeed, we pre-
viously found that BAX K21E mutagenesis slows the kinetics ofChemistry & Biology 20,(but does not wholly abrogate) direct BAX activation by BIM
and BAX BH3 helices in vitro and in Bax/Bak/ mouse em-
bryonic fibroblasts (MEFs) reconstituted with BAX K21E and
exposed to staurosporine (Gavathiotis et al., 2008, 2010). In
addition, recombinant BAX is unable to undergo heat-induced
oligomerization in solution upon K21E (trigger site) or E69K
(BH3 domain) mutagenesis, but activity is fully restored in the
double K21E, E69K mutant (Gavathiotis et al., 2010), further
underscoring the functional relevance of activator BH3 domain
interaction at the a1/a6 trigger site in initiating and propagating
BH3-mediated direct activation of full-length BAX.
Here, we find that R142E mutagenesis of expressed PUMA
protein eliminates coimmunoprecipitation with endogenous
MCL-1, BCL-2, and BAX, whereas PUMA D147K mutagenesis
only disrupts the BAX interaction (Figure 7G). These data rein-
force that PUMA engages BCL-2 family multidomain canonical
pockets and the BAX a1/a6 site, as reflected by binding sensi-
tivity to PUMA R142E mutagenesis, which establishes a
charge-charge repulsion with MCL-1 D237 and, by analogy,
with BCL-2 D140 and BAX D102 at the canonical sites, and
BAX E131 at the a1/a6 site (Figures S4B–S4E). In contrast,
PUMA D147 projects away from the canonical pocket of MCL-1
(Figure S4B), and also has no electrostatic pairing at the BAX ca-
nonical site (Figure S4D), yet would be predicted to interact with
the functionally relevant K21 residue at the BAX a1/a6 site based
on the calculated model structure of a BIM BH3 helix bound to
full-length BAX (Figure S4E). Indeed, we find that PUMA D147K
mutagenesis selectively impairs coimmunoprecipitation with
native BAX but spares the interactions with antiapoptotic BCL-
2 and MCL-1 (Figure 7G). Further, the finding that PUMA D147K
mutagenesis alone disrupts BAX binding is consistent with our
NMR, crosslinking, and FP analyses, all of which indicate that
the site of first contact between PUMA BH3 and full-length BAX
is at the a1/a6 trigger site. Taken together, our data demonstrate
thatPUMABH3harbors thebiochemical capacity to engageboth
anti- and proapoptotic BCL-2 family proteins in a sequence-spe-
cificmanner and, depending on the cellular context, may harness
this multimodal interaction potential to activate the apoptotic
pathway.
DISCUSSION
PUMA is a potent proapoptotic BH3-only protein implicated in a
variety of apoptotic signaling pathways and subject to transcrip-
tional and posttranslational regulation (Jeffers et al., 2003). Like
BIM, PUMA broadly interacts with BCL-2 family antiapoptotic
proteins, and the two proteins have been shown to compensate
for and cooperate with one another in a variety of physiologic
death pathways (Erlacher et al., 2005, 2006; Garrison et al.,
2012; Gray et al., 2012). In addition, PUMA has recently been
shown to promote apoptosis by selectively displacing p53
from antiapoptotic BCL-XL via an allosteric mechanism (Follis
et al., 2013). Published biochemical, cellular, and in vivo studies
differ, however, on whether a component of PUMA’s proapopto-
tic potency also derives from its capacity to directly engage pro-
apoptotic proteins, as demonstrated for BID and BIM. Notably,
alignment of BCL-2 family BH3 domains reveals that PUMA
BH3 is most similar to the BH3 domains of BIM and BAX in the
very region implicated in direct interaction at the recently888–902, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 897
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the defined BIM BH3 triggering and BAX BH3 autopropagating
interactions at the a1/a6 site (Gavathiotis et al., 2008, 2010), it
seemed likely that PUMA BH3 could likewise bind BAX at this
same location. Indeed, by a series of distinct methods, including
NMR spectroscopy, mass spectrometry, fluorescence polariza-
tion binding, and coimmunoprecipitation analyses, we identified
PUMA BH3 interaction at the a1/a6 interface of full-length BAX.
We linked this binding event to direct and functional activation of
BAX in both liposomal and mitochondrial assay systems, in
which PUMA SAHB dose responsively triggered BAX-mediated
release activity in a BH3 sequence-dependent manner. The
physiologic relevance of these structural and biochemical find-
ings are supported by the capacity of PUMA SAHB and
PUMA protein to likewise engage native antiapoptotic BCL-2
family proteins and proapoptotic BAX from cells. Taken together,
these data support a model in which PUMA can function as a
direct activator of BAX, consistent with a recent study docu-
menting that in the absence of the direct activators BID, BIM,
and p53, PUMA was sufficient to activate BAX (Garrison et al.,
2012).
In mapping the PUMA BH3 interaction site by pSAHB-based
photoaffinity labeling, the majority of crosslinked residues in
full-length BAX localized to the a1/a6 trigger site, yet a small
subset included residues of the canonical BH3-binding pocket.
As the initial chemical shift changes observed by NMR upon
PUMA SAHBA1 binding localize to surface residues of the a1/
a6 trigger site, we conclude that allosteric release of a9 upon
triggering at the N-terminal site exposes the canonical pocket,
which is likewise compatible with PUMA BH3 binding. Indeed,
when we performed the MS-based site identification analyses
with C-terminally deleted BAX, the PUMA pSAHB crosslinking
pattern shifted to predominantly involve residues of the canon-
ical pocket. This dual but sequential compatibility of PUMA
BH3 binding at distinct sites on BAX was further supported
by FP analyses using two constructs of BAX that favor interac-
tion either at its N-terminal trigger site or canonical pocket. A
similar compatibility for activator BH3 domains at the tradi-
tional BH3-binding pocket was also observed for C-terminally
deleted BAX by X-ray crystallography (Czabotar et al., 2013).
It is noteworthy that these structural analyses of select acti-
vator BH3 domains in stable complex with BAXDC only
captured the canonical pocket interaction, just as our MS ana-
lyses with BAXDC markedly favored crosslinking to canonical
site residues. However, in the context of the full-length BAX
protein, our NMR, MS, and binding analyses demonstrate pri-
mary BH3 engagement of the a1/a6 trigger site, a key regula-
tory feature that is missed when studying C-terminally trun-
cated BAX protein. Interestingly, a series of recent studies
performed with full-length (Leshchiner et al., 2013) and
C-terminally deleted (Dai et al., 2011; Moldoveanu et al.,
2013) BAK protein, which in its native state constitutively re-
sides in the outer mitochondrial membrane, identified direct
BH3 interactions exclusively at the canonical site. Taken
together, these data suggest that activator BH3-engagement
at the canonical pocket may represent a common mechanism
for propelling the activation of mitochondrial-localized BAK and
BAX, with the a1/a6 triggering mechanism of BAX representing
a unique afferent step required to regulate the activation and898 Chemistry & Biology 20, 888–902, July 25, 2013 ª2013 Elsevier Lmitochondrial translocation of cytosolic BAX (Walensky,
2013a, 2013b).
The stability and high affinity of BH3-only interactions with
antiapoptotic BCL-2 family proteins suggest that upon BH3-
only deployment in response to cellular stress, the principal
wrestling site between prolife and prodeath forces may reside
in these neutralizing complexes. However, with continued pro-
apoptotic signaling, displacement of activator BH3-only proteins
from antiapoptotics or depletion of the antiapoptotic reservoir,
produces a BID/BIM/PUMA overflow that directly activates
BAX and BAK at their respective BH3 trigger sites. Hydrocar-
bon-stapled peptides modeled after the BH3 domain helices of
BCL-2 family proteins have proven to be high fidelity tools for
dissecting physiologically relevant binding interfaces and mech-
anisms (Gavathiotis et al., 2008, 2010; Stewart et al., 2010; Wa-
lensky et al., 2006), while also serving as prototype therapeutics
for the modulation of apoptosis in vivo (LaBelle et al., 2012; Wa-
lensky et al., 2004). Whereas BAD and NOXA SAHBs recapitu-
late the finely tuned selectivities of the corresponding native
BH3-only proteins (Stewart et al., 2010; Walensky et al., 2006),
BID, BIM, and PUMA SAHBs manifest the broad antiapoptotic
targeting capacity and direct BAX and BAK triggering activity
of their cognate proteins (Gavathiotis et al., 2008; Leshchiner
et al., 2013; Walensky et al., 2006). Importantly, the very potency
of PUMA and the capacity of its BH3 helix to engage native anti-
and proapoptotic BH3-binding pockets, suggests that pharma-
cologic mimicry of this dual functionality carries the potential to
reactivate apoptosis in the context of resistant cancer, as
observed here for neuroblastoma. Indeed, the BH3-binding
pockets of both anti- and proapoptotic BCL-2 family proteins
are bona fide drug targets. Whereas therapeutic targeting of
the antiapoptotic BCL-2/BCL-XL or BCL-2 canonical grooves
in the form of ABT-737/ABT-263 and ABT-199, respectively,
has led the way for ‘‘inhibiting the inhibitors’’ of apoptosis
(Oltersdorf et al., 2005; Souers et al., 2013; Tse et al., 2008),
new approaches to ‘‘activating the activators’’ by simulating
BID, BIM, and PUMA engagement of BH3 trigger sites on BAX/
BAK are underway (Gavathiotis et al., 2012; LaBelle et al.,
2012) and may add a new dimension to the growing arsenal of
BCL-2 family modulators.
SIGNIFICANCE
BH3-only proteins are critical modulators of mitochondrial
apoptosis, and their array of protein interactions provide
blueprints for the development of therapeutics to manipu-
late the death pathway for clinical benefit. TheBH3-only pro-
teins BID and BIM have been implicated in direct triggering
interactions with multidomain proapoptotic BCL-2 family
members such as BAX and BAK, but whether PUMA is
also a member of this direct activator group has been a
long-standing controversy in the cell death field. We sought
to address this issue using multidisciplinary chemical
biology approaches, including NMR structural analysis,
photoreactive-stapled peptide crosslinking and MS-based
binding site identification, and correlative biochemical and
cellular assays. We report that a PUMA BH3 helix directly
binds to BAX at the a1/a6 trigger site, resulting in its func-
tional activation. Once the a9 helix of BAX is allostericallytd All rights reserved
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groove of BAX is also compatible with PUMA BH3
binding. These data provide direct evidence of a sequential
binding mode for activator BH3 domains in triggering the
activation and mitochondrial translocation of BAX and then
propelling the activated state at the mitochondrial mem-
brane to facilitate oligomerization. We validate our in vitro
findings in the cellular context, demonstrating that (1) a
cell-permeable PUMABH3 helix induces caspase 3/7 activa-
tion and cell death of neuroblastoma cell lines, and (2) both
biotinylated PUMA BH3 helix and expressed full-length
PUMAprotein engage native antiapoptotic and proapoptotic
proteins from cells. Thus, we provide structural, biochem-
ical, and cellular evidence for how PUMA, a critical proapo-
ptotic mediator of p53-dependent and p53-independent
apoptotic responses, transmits its death message through
multimodal protein interaction. PUMA mimetics with dual
capacity to ‘‘inhibit the inhibitors’’ and directly ‘‘activate
the activators’’ of cell death hold promise to overcome the
apoptotic resistance of human cancers.
EXPERIMENTAL PROCEDURES
Stapled Peptide Synthesis and Characterization
SAHBs were synthesized, derivatized, purified to >95% homogeneity by LC/
MS, quantified by amino acid analysis, and subjected to circular dichroism
(Aviv Biomedical spectrophotometer) in 5 mM potassium phosphate buffer
(pH 7.4), as previously described (Bird et al., 2008, 2011; Braun et al., 2010).
All BH3 peptides generated and applied in the biochemical, structural, and
cellular analyses are listed in Table S1.
Recombinant Protein Production
BCL-2DC, BCL-XLDC, BCL-wDC, MCL-1DNDC, BFL-1/A1DC, BAXDC, and
full-length BAX proteins were produced and purified as described previously
(Gavathiotis et al., 2008; LaBelle et al., 2012). Briefly, BCL-2DC, BCL-XLDC,
BCL-wDC, and MCL-1DNDC were expressed as glutathione S-transferase
(GST) fusion proteins in Escherichia coli BL21 (DE3) from the pGEX2T vector
(Pharmacia Biotech) and purified by affinity chromatography using glutathione
sepharose beads (GE Healthcare), followed by thrombin cleavage of the GST
tag. GB1-BFL-1/A1DC-His was expressed in Escherichia coli BL21 (DE3) from
the pGEV2 vector, purified by affinity chromatography using nickel-NTA
agarose beads (QIAGEN), and eluted in accordance with the manufacturer’s
instructions. BAX, BAXDC, and BAX A112C/V177C were expressed in E. coli
BL21 (DE3) from the pTYB1 vector and purified by affinity chromatography us-
ing chitin beads (New England Biolabs), and the chitin tag cleaved by overnight
incubation in 50 mM dithiothreitol. In each case, pure, monomeric protein was
isolated by gel filtration fast protein liquid chromatography.
Fluorescence Polarization Binding Assay
FITC-PUMA SAHBs (50 nM) were added to serial dilutions of recombinant pro-
tein in binding buffer (antiapoptotic binding: 100mMNaCl, 50mMTris [pH 8.0];
BAX binding: 140 mM NaCl, 50 mM Tris [pH 7.4]) in 96-well black opaque
plates. For binding assays employing BAX A112C/V177C, the protein stock
and binding buffer was supplemented with glutathione disulfide (GSSG)
(0.5 mM). The plates were incubated in the dark at room temperature and
then fluorescence polarization measured at 20 min on a microplate reader
(Spectramax M5 Microplate Reader, Molecular Devices). Dissociation con-
stants (KD) were calculated by nonlinear regression analysis of dose-response
curves with Prism software 5.0 (GraphPad).
NMR Analysis
Uniformly 15N-labeled full-length human BAX was generated as previously
described (Gavathiotis et al., 2008; Suzuki et al., 2000). Protein samples
were prepared in 25 mM sodium acetate, 50 mM NaCl solution at pH 6.0 inChemistry & Biology 20,5% D2O. PUMA SAHBA1 (6 mM stock) was titrated into a solution of 50 mM
BAX to achieve the indicated molar ratios. Correlation 1H-15N HSQC spectra
(Grzesiek and Bax, 1993) were acquired at 25C on a Bruker 800 MHz NMR
spectrometer equipped with a cryogenic probe, processed using NMRPipe
(Delaglio et al., 1995), and analyzed with NMRView (Johnson, 2004). The
weighted average chemical shift difference D at the indicated molar ratio
was calculated as [{(DH)2 + (DN/5)2}/2]1/2 in ppm. The absence of a bar indi-
cates no chemical shift difference or the presence of a proline or residue
that is overlapped or not assigned. BAX cross-peak assignments were applied
as previously reported (Suzuki et al., 2000). The significance threshold for
backbone amide chemical shift changes was calculated based on the average
chemical shift across all residues plus the standard deviation, in accordance
with standard methods (Marintchev et al., 2007).
Binding Site Identification by pSAHB Photoaffinity Labeling and
Mass Spectrometry
Recombinant protein (10 mM) and biotinylated pSAHB (30 mM) were mixed and
then irradiated (365 nm, Spectroline Handheld UV LampModel En280L, Spec-
tronics) for 1.5 hr on ice. Unreacted peptide was removed from the irradiated
samples by overnight dialysis at 4C in dialysis buffer (200 mM NaCl, 50 mM
Tris [pH 7.5]) using 6–8 kDa molecular weight cutoff D-Tube dialyzers (EMD
Biosciences). Biotinylated species were captured by incubation with high-
capacity streptavidin agarose (Thermo Scientific) for 2 hr at 4C. Streptavidin
beads were sequentially washed at room temperature three times each in 1%
SDS in PBS, 1 M NaCl in PBS, and 10% ethanol in PBS and boiled 23 10 min
in a 10% SDS solution (Promega) containing D-biotin (10 mg/ml). The eluates
were electrophoresed using 4%–12% gradient Bis-Tris gels (Invitrogen) and
then stained for protein content by Coomassie blue. The crosslinked bands
were excised and prepared for mass spectrometry analysis as previously
described (Braun et al., 2010). Samples were subjected to liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) in an LTQ Orbitrap XL hybrid
mass spectrometer (Thermo Fisher Scientific). MS/MS spectra were searched
using the SEQUEST algorithm (Yates et al., 1995) against a partially tryptic
database of the relevant protein. Benzophenone-crosslinked tryptic fragments
were identified by using the mass of the tryptic fragment of the pSAHB peptide
as a required modification. Reversed protein sequences were used to
generate an estimate of the false discovery rate. Identified crosslinked pep-
tides were filtered based on tryptic state, charge state, mass accuracy, and
number of crosslinks per peptide.
Liposomal Release Assay
Liposomes were generated and applied in BAX-mediated release assays as
described previously (Gavathiotis et al., 2010; Yethon et al., 2003). Briefly, a
lipid mixture composed of a 48:28:10:10:4 molar ratio of phosphatidylcholine,
phosphatidylethanolamine, phosphatidylinositol, dioleoyl phosphatidylserine,
and tetraoleolyl cardiolipin (Avanti Polar Lipids) in chloroform was generated
to mimic the lipid composition of the outer mitochondrial membrane. Solvent
was removed by evaporation under nitrogen gas and then by vacuum for 2 hr.
Lipid films were hydrated in liposome buffer (150 mM KCl, 20 mM HEPES
[pH 7.0]) and mixed with 12.5 mM ANTS fluorophore and 45 mM DPX
quencher. After five freeze-thaw cycles, the mixture was extruded through
100 nm nucleopore polycarbonatemembranes (Avestin), and intact liposomes
were purified by gel filtration chromatography using a 10 ml Sepharose CL2B
column (GE Healthcare). To monitor ligand-triggered BAX-mediated release,
liposomes were incubated in liposome buffer with the indicated amounts of re-
combinant monomeric BAX and PUMA SAHBs in black opaque 96-well plates
(total reaction volume, 100 ml). ANTS/DPX release was monitored over a
120 min period in a spectrofluorometer (Tecan Infinite M1000) using an excita-
tion wavelength of 355 nm, an emission wavelength of 540 nm, and a band-
width of 20 nm. Maximal release was determined by addition of Triton X-100
to a final concentration of 0.2% (v/v). Percent release was calculated as
[(F-F0)/(F100-F0)] 3 100, where F is the observed release, and F0 and F100 are
baseline and maximal fluorescence, respectively.
Cytochrome c Release Assay
Mouse liver mitochondria (1.0 mg/ml) were isolated from Alb-
creposBaxfl/-Bak/ mice as described (Pitter et al., 2008) and incubated with
the indicated combinations of recombinant BAX and PUMA SAHBs at 37C888–902, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 899
Chemistry & Biology
Dissecting the Apoptotic Interactions of PUMA BH3for 40 min. The pellet and supernatant fractions were isolated by centrifuga-
tion, and released cytochrome c was quantitated using a colorimetric ELISA
assay (R&D Systems). Percent cytochrome c released into the supernatant
(%cytocsup) from releasable mitochondrial pools was calculated according
to the following equation: %cytoc = [(cytocsup  cytocbackgr)/(cytoctotal 
cytocbackgr)] 3 100, where background release represents cytochrome c de-
tected in the supernatant of vehicle-treated samples, and total release repre-
sents cytochrome c measured in 1% Triton X-100-treated samples.
Cell Culture
Wild-type (WT) and Bax/Bak/ (DKO) mouse embryonic fibroblasts (MEFs)
and human embryonic kidney (HEK) 293T cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen) supplemented with 10% FBS,
100 U/ml penicillin/streptomycin, 2 mM L-glutamine, 0.1 mM nonessential
amino acids, and 50 mM b-mercaptoethanol. Neuroblastoma cell lines SH
SY5Y, Kelly, and IMR5 were maintained in RPMI 1640 GlutaMAX (Invitrogen)
supplemented with 10% FBS and 100 U/ml penicillin/streptomycin.
Cellular Uptake Analysis
SH SY5Y cells were plated in 6-well plates at 5 3 105 cells per well, and after
overnight incubation, full media was removed and replaced with OptiMEM
(Invitrogen) containing 100 U/ml penicillin/streptomycin and either no or the
indicated amount of added serum. FITC-PUMA peptide (1 mM stock in
DMSO) or vehicle was diluted into 1 ml cultures for a final treatment concen-
tration of 5 mM and incubated at 37C for 6 hr, followed by washing twice in
PBS, trypsinizing for 10 min to remove any surface-bound peptide, and
washing in PBS twice more. Cells were then lysed in 1% CHAPS buffer on
ice and incubated for 20 min. Supernatants were collected after table-top
centrifugation, electrophoresed, and intracellular FITC peptide detected by
fluorescence imaging using a Typhoon 9400 (GE Healthcare). For live cell
confocal microscopy, SH SY5Y cells were plated in poly-D-lysine-coated cul-
ture plates (MatTek Corporation) at 2 3 105 cells per well, and after overnight
incubation, full media was replaced with OptiMEM (Invitrogen) containing
100 U/ml penicillin/streptomycin. FITC-PUMA peptide (1 mM stock in
DMSO) or vehicle was diluted into 1 ml cultures for a final treatment concen-
tration of 10 mM and incubated at 37C. After 6 hr, cells were incubated with
CellMask Orange (5 mg/ml) and Hoeschst 33342 (5 mg/ml, Invitrogen) for
10 min, followed by washing three times with PBS and incubation with
DMEM media lacking phenol red. Confocal images were acquired on a Yoko-
gawa CSU-X1 spinning disk confocal system (Andor Technology) attached to
a Nikon Ti-E inverted microscope (Nikon Instruments). Excitation of the three
fluorophores was performed sequentially using 405, 488, and 561 nm lasers.
Images were acquired using a 1003 Plan Apo objective lens with a Hama-
matsu OrcaER camera (Hamamatsu Photonics). Acquisition parameters, shut-
ters, filter positions, and focus were controlled by Andor iQ software (Andor
Technology).
Cell Viability and Caspase-3/7 Activation Assays
Cells were plated in 96-well plates at 2.5 3 103 cells per well, and after over-
night incubation, full media was replaced with OptiMEM containing 100 U/ml
penicillin/streptomycin and no added serum. A serial dilution of PUMASAHBA2
from a 10mMDMSO stock or vehicle was added to the cells in a final volume of
100 ml and incubated at 37C for 6 hr, followed by addition of 10 ml FBS (serum
replacement to 10% [v/v]). For the correlative cellular uptake and viability an-
alyses (Figures 6E and 6F), the culture media during the initial 6 hr treatment
period contained either no added serum or 2.5%, 5%, or 10% [v/v] FBS. To
measure caspase-3/7 activation, cells were analyzed after 8 hr of total treat-
ment using the Caspase-Glo 3/7 chemiluminescence reagent (Promega). For
cell viability analysis, cells were analyzed after 24 hr of total treatment using
the CellTiter-Glo chemiluminescence reagent (Promega). Luminescence was
detected by a microplate reader (Spectramax M5 Microplate Reader, Molec-
ular Devices).
PUMA SAHB Coprecipitation from Cellular Lysates
Neuroblastoma cells were trypsinized, collected by centrifugation, washed
twice in cold PBS, and lysed in a 1% CHAPS buffer (50 mM Tris [pH 7.5],
200 mM NaCl, 1% [w/v] CHAPS, 1 mM EDTA, 1.5 mM MgCl2, complete
protease inhibitor tablet [Roche]) on ice for 20 min. Lysates were isolated after900 Chemistry & Biology 20, 888–902, July 25, 2013 ª2013 Elsevier Ltable-top centrifugation and then 1.25 mg of lysate was incubated with
50 nmol biotinylated-PUMA SAHBA3 in lysis buffer overnight at 4
C. Biotin
pull-down was accomplished by incubation with high-capacity streptavidin
agarose (Thermo Scientific) for 2 hr at 4C, followed by washing the beads
with 3 3 500 ml lysis buffer. Precipitated proteins were eluted by treating the
beads with 4x LDS buffer containing 50 mM DTT for 10 min at 70C and
then subjected to electrophoresis (25 mg protein/lane) and western blotting
using the following antibodies: BAX N-20 (1:2,000) (sc-493, Santa Cruz
Biotechnology), BCL-2 (1:200) (sc-509, Santa Cruz), MCL-1 s-19 (1:200) (sc-
819, Santa Cruz), and GAPDH 6C5 (1:200) (sc-32233, Santa Cruz).
Cell Transfection and Flag-PUMA Coimmunoprecipitation
HEK 293T cells were transiently transfected with pcDNA3 plasmid containing
Flag-PUMAa or its R142E or D147Kmutants, using polyethylenimine (PEI) (Ye-
thon et al., 2003) at a 4:1 PEI:DNA ratio. Two days following transfection, cells
were lysed in 1% CHAPS buffer (as above), and isolated lysate (2 mg) was
incubated with 30 ml of anti-Flag magnetic affinity beads (Sigma) in lysis buffer
overnight at 4C. The beads were washed with 3 3 500 ml lysis buffer, and
immunoprecipitated proteins were eluted by incubation with 4x LDS contain-
ing 50 mMDTT for 10 min at 70C. The immunoprecipitates were subjected to
electrophoresis and analyzed by western blot using the above-described BAX,
BCL-2, MCL-1, and GAPDH antibodies.
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